India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant
02/09/2026 09:31
BUZZ-India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant ** Pharma firm Gland Pharma's shares GLAD.NS rise as much as 1.91% to 2,930 rupees apiece, bucking the weakness in the broader market on higher crude
** GLAD last up 0.7%; pharma index .NIPHARM trades flat
** U.S. drug regulator has concluded its inspection at the drugmaker's Visakhapatnam facilities with zero observations
** A zero-observation U.S. FDA inspection indicates no compliance issues were identified at Gland Pharma's Visakhapatnam facilities, strengthening confidence in its manufacturing capabilities
** GLAD shares are up 68% in 2026 so far, outperforming the 17.8% rise in pharma index, exchange data shows
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Gland Pharma
See all newsIndia Stocks: Indian shares open higher as Fed-hike fears, oil prices ease; financials lead
India Stocks: Indian shares poised to rebound as Fed-hike fears, oil prices ease
Brief: Gland Pharma Approves $21 Million Investment In Gland Pharma Usa
Brief: Fosun Pharma Says Unit Sold Gland Pharma Shares for $294 Mln
India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant